Long‐term survival after surgery of pancreatic primary squamous cell carcinoma: A case report and literature review

Taïbi, Abdelkader; Jacques, Jérémie; Fontanier, Sylvaine Durand; Charissoux, Aurélie; Bardet, Sylvia M.; Christou, Niki; Fredon, Fabien; Valleix, D.; Mathonnet, Muriel

doi:10.1002/ccr3.2429

Cited by 4 publications

(10 citation statements)

References 47 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The stereotype of patient diagnosed with primary pancreatic carcinomas with squamous component is, like our cases, a male in his 6 th decade of life showing an infiltrative tumor of the head of the pancreas [9,10].…”

Section: Discussionsupporting

confidence: 51%

See 1 more Smart Citation

Adenosquamous and squamous cell carcinoma of the pancreas: two histopathological variants of ductal adenocarcinoma

Szekely¹,

Togănel

Kádár

et al. 2021

Acta Marisiensis - Seria Medica

View full text Add to dashboard Cite

Introduction: Primary squamous cell carcinoma (SCC) and adenosquamous carcinoma of the pancreas are rare malignancies for which diagnostic and treatment strategy are challenging. In this paper we present a literature review of these tumors based on two case reports. Case presentation: In the first case, a 55-year-old male presented with an inoperable pancreatic head/body junction tumor. Endoscopic ultrasound-guided fine needle aspiration was practiced, and histopathological examination revealed a squamous cell carcinoma of the pancreas. After exclusion of any another tumor, the diagnosis of cT4N0M0-staged primary pancreatic SCC was made. The patient is under treatment with gemcitabine and oxaliplatin. The second case is represented by a 73-year-old patient in which imagistic examinations highlighted a cystic mass of the pancreatic body. Following coporeo-caudal splenic-pancreatectomy and histopathological-proved diagnosis of adenosquamous carcinoma, the patient started chemotherapy but died at 11 months after surgery. Both tumor components displayed positivity for markers which prove ductal (cytokeratin19, maspin) and squamous differentiation (p63, cytokeratin5/6) same as vimentin, as indicator of epithelial mesenchymal transition (EMT). Conclusions: SCC and adenosquamous carcinoma of the pancreas are aggressive malignancies which prognosis remains highly reserved. These tumors might be variants of ductal adenocarcinomas which are dedifferentiated through EMT phenomenon.

show abstract

Section: Discussionsupporting

confidence: 51%

“…[1,3,[6][7][8]17,22]. Although nabpaclitaxel seems to be superior to platinum salts ones [10], it is not reimbursed in medium-income countries and gemcitabile is the therapy of choice in such cases. Immunotherapy might be the election choice in cases with high PD-L1 expression [17].…”

Section: Discussionmentioning

confidence: 99%

Adenosquamous and squamous cell carcinoma of the pancreas: two histopathological variants of ductal adenocarcinoma

Szekely¹,

Togănel

Kádár

et al. 2021

Acta Marisiensis - Seria Medica

View full text Add to dashboard Cite

show abstract

“…However, the standard care for the metastatic setting is still lacking ( 9 , 10 ). Data from sporadic reports revealed that 38.5% of metastatic patients received palliative care, and others commonly underwent a combination of cisplatin and 5‐fluorouracil or gemcitabine, showing a short median OS of 4 months, compared with 17 months in the resectable group and 8 months in the locally advanced tumor group ( 11 ). A pool of data regarding pancreatic SCC available in the public domain showed a median OS of 7 months in 54 patients with pancreatic SCC, and resectable cases had significantly better OS when compared with non-resectable cases (10 months versus 4 months, respectively) ( 10 ).…”

Section: Discussionmentioning

confidence: 99%

“…reported a case of a locally advanced SCC of the pancreatic tail showing an OS of 1 year following treatment with an albumin-free nanosomal paclitaxel lipid suspension-based regimen ( 13 ). A recent study described a patient with T2N0M0R0 primary SCC of the pancreas, who received chemotherapy of gemcitabine following surgery and achieved a long relapse-free survival of 26 months ( 11 ).…”

Section: Discussionmentioning

confidence: 99%

The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report

Huang

Ma²,

Huang³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Pancreatic squamous cell carcinoma (SCC) is a rare primary pancreatic malignancy with a poor prognosis. The median overall survival (OS) for metastatic setting is only 4 months and the optimal management remains poorly defined. In the present study, we report a 52-year-old female patient with stage IV primary SCC of the pancreas harboring a deleteous BRCA2 somatic mutation. After 10 cycles of chemotherapy of cisplatin combined with nanoparticle albumin-bound paclitaxel, metastatic lesions in the liver and lymph nodes achieved radiographic complete responses and pancreatic lesion shrank from 5.7 to 1.5 cm in diameter. The patient subsequently underwent a posterior radical antegrade modular pancreatosplenectomy with R0 resection and residual liver lesions were also resected. After 3 months, a tumor relapsed in the liver. She was then treated with olaparib combined with pembrolizumab and achieved stable disease on the liver lesion. The patient eventually died from cerebral hemorrhage with a long OS of 21 months. Our case demonstrated a favorable clinical activity and survival advantage of the combined cisplatin and nanoparticle albumin-bound paclitaxel, which might serve as a therapeutic option for the patient with BRCA-mutant pancreatic SCC.

show abstract

“…As per the other types of PC, surgical resection is the only curative approach for ASPC and SCC , that can significantly improve survival[ 107 , 110 , 119 , 120 ]. Patients affected by ASPC or SCC undergoing surgery and post-operative treatment with chemotherapy, radiotherapy or both appear to have a benefit[ 108 , 121 - 123 ], even though there is no consensus regarding the best regimen to use, that are commonly fluoropyrimidine-based, gemcitabine based or platinum-based.…”

Section: Adenosquamous Carcinoma and Squamous Cell Pancreatic Carcinomentioning

confidence: 99%

One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches

Niger

Prisciandaro

Antista

et al. 2020

WJGO

View full text Add to dashboard Cite

Exocrine pancreatic neoplasms represent up to 95% of pancreatic cancers (PCs) and are widely recognized among the most lethal solid cancers, with a very poor 5-year survival rate of 5%-10%. The remaining < 5% of PCs are neuroendocrine tumors that are usually characterized by a better prognosis, with a median overall survival of 3.6 years. The most common type of PC is pancreatic ductal adenocarcinoma (PDAC), which accounts for roughly 85% of all exocrine PCs. However up to 10% of exocrine PCs have rare histotypes, which are still poorly understood. These subtypes can be distinguished from PDAC in terms of pathology, imaging, clinical presentation and prognosis. Additionally, due to their rarity, any knowledge regarding these specific histotypes is mostly based on case reports and a small series of retrospective analyses. Therefore, treatment strategies are generally deduced from those used for PDAC, even if these patients are often excluded or not clearly represented in clinical trials for PDAC. For these reasons, it is essential to collect as much information as possible on the management of PC, as assimilating it with PDAC may lead to the potential mistreatment of these patients. Here, we report the most significant literature regarding the epidemiology, typical presentation, possible treatment strategies, and prognosis of the most relevant histotypes among rare PCs.

show abstract

Long‐term survival after surgery of pancreatic primary squamous cell carcinoma: A case report and literature review

Abstract: Pancreatic primary squamous cell carcinoma is rarer and no optimal treatment has been validated according to the tumor stage. The surgical resection was the only curative option. The radiotherapy or chemotherapy was performed for the other cases.

Cited by 4 publications

References 47 publications

Adenosquamous and squamous cell carcinoma of the pancreas: two histopathological variants of ductal adenocarcinoma

Adenosquamous and squamous cell carcinoma of the pancreas: two histopathological variants of ductal adenocarcinoma

The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report

One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches

Contact Info

Product

Resources

About